TIDMHIK
RNS Number : 2871K
Hikma Pharmaceuticals Plc
20 September 2016
Board Appointment and Succession
London, 20 September 2016 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) (Hikma), the fast growing pharmaceuticals company, is
today announcing the following changes to its Board
composition.
Nina Henderson
The Board is pleased to confirm that with effect from 1 October
2016, Nina Henderson is to join the Board as an independent
non-executive director. Nina will become a member of the Audit,
Remuneration and Nomination Committees.
Nina is a former Corporate Vice President of Bestfoods where she
held numerous international general management and executive
marketing positions for global consumer branded and food service
businesses. During a 30 year career, her positions included
President Bestfoods Grocery North America Consumer Division,
Corporate Vice President Business Development Global Food Service
Division, President Bestfoods Specialty Markets Division, Vice
President Bestfoods Baking until 2001.
Nina has served as a Director of Royal Dutch Shell PLC, AXA
Financial Inc., The Equitable Companies, Del Monte Foods Company,
Hunt Corporation, Pactiv Corporation and Walter Energy Inc. with
service on Audit, Investment, Nomination and Governance, Corporate
Social Responsibility and Remuneration Committees. She has served
as a Lead Director and committee Chair.
Nina is an honours graduate of Drexel University and holds a
Bachelor of Science. A member of the Drexel 100, she received the
Anthony J. P. Drexel Distinguished Alumni Award in 2010.
Nina is a Director of Regus PLC, where she is Chair of the
Remuneration Committee and CNO Financial Group Inc. which owns
Bankers Life, Washington National and Colonial Penn insurance
companies offering life and health care policies. Nina is a
Director of the Visiting Nurse Service of New York Inc. ('VNSNY')
including VNSNY Choice Health Insurance and VNSNY Home Health Care,
the largest home health care provider in the United States. She is
a Trustee of Drexel University, including the Drexel College of
Medicine, the largest private medical school in the United States,
where she is Chair of the Academic Affairs Committee and serves on
Executive and Finance committees. Nina is a Director of the Foreign
Policy Association and President of the Kent Land Trust Foundation,
a nature conservancy.
Board Changes
The Board wishes to confirm its plans for the retirement of two
Independent Directors.
Michael Ashton, who joined the Board in November 2005, will step
down at the 2017 AGM. Michael chaired the Remuneration Committee
until May 2016 and has overseen an orderly transfer of his
responsibilities to Dr. Pamela Kirby.
Ron Goode, who joined the Board in December 2006 and chairs the
Compliance, Responsibility and Ethics Committee (CREC), will step
down at the 2018 AGM.
In addition to their knowledge of Hikma and the committees with
which they are involved, the two retiring Directors have
substantial pharmaceutical experience which the Board will seek to
replace in due course. The Board wishes to an orderly transfer of
responsibilities and knowledge.
Committee Changes
The Board has reviewed its structure, including the composition
of the Board committees and wishes to announce the following
changes:
The Nomination Committee will be renamed the Nomination and
Governance Committee, reflecting the committee's additional
responsibilities.
Pat Butler, the Chair of the Audit Committee, will become a
member of the Remuneration Committee with immediate effect.
John Castellani will formally take the chair of the CREC at the
end of the May 2017 AGM, following a period of shadowing Ron Goode,
who will be handing over the CREC chair.
Said Darwazah, Chairman and Chief Executive, said: I am
delighted that Nina has agreed to join the Board. She will bring a
wealth of executive and leadership experience which will greatly
assist us as we take Hikma to the next stage of its
development.
Michael and Ron have made invaluable contributions to Hikma,
both in their work on their committees and in their expert
knowledge of the global pharmaceuticals market. Fortunately, we
will continue to benefit from their wisdom for a while longer until
they both retire from the Board.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, VP for Corporate Strategy and IR +44 (0)20 7399 2760
FTI Consulting
Ben Atwell / Matthew Cole +44 (0)20 3727 1000
Notes to Editors:
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAAKKDBPBKKACB
(END) Dow Jones Newswires
September 20, 2016 02:01 ET (06:01 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024